Xarelto is not expected to go generic in 2024. The drug's primary patents are set to expire later.
When Does Xarelto's Main Patent Expire?
The key patent protecting Xarelto (rivaroxaban) is set to expire in November 2024 [1]. However, this expiration does not immediately open the door for generic versions.
Why Aren't Generics Available Immediately After Patent Expiry?
Even after a primary patent expires, other factors can delay generic competition. These can include secondary patents covering manufacturing processes, formulations, or specific uses of the drug. Litigation surrounding these patents can also prolong exclusivity [2].
Are There Other Patents on Xarelto?
Yes, Xarelto has faced multiple patent challenges and has several secondary patents. These patents, along with any ongoing legal disputes, can influence the timeline for generic market entry. Information on specific patent expirations and litigation can be found on resources like DrugPatentWatch.com [1][2].
What is the Expected Timeline for Xarelto Generics?
With the primary patent expiring in late 2024, generic versions of Xarelto could potentially become available in 2025, depending on the outcomes of any remaining patent disputes and the FDA's approval process for generic applications.
Who is Developing Generic Xarelto?
Several pharmaceutical companies have expressed interest in developing generic versions of rivaroxaban. Companies that have filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for generic rivaroxaban include Teva Pharmaceuticals, Apotex, and Viatris [3].
What is the Mechanism of Action for Xarelto?
Xarelto is a direct oral anticoagulant that works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade [1]. This inhibition reduces the formation of thrombin, thereby preventing blood clots.
What are the Uses of Xarelto?
Xarelto is prescribed to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [1].
What are the Risks Associated with Xarelto?
The primary risk associated with Xarelto, like other anticoagulants, is bleeding [1]. Patients taking Xarelto should be monitored for signs and symptoms of bleeding.
How Does Xarelto Compare to Other Anticoagulants?
Xarelto is a direct oral anticoagulant (DOAC) and belongs to the same class as apixaban (Eliquis) and dabigatran (Pradaxa). These DOACs are often compared to warfarin, an older anticoagulant, with DOACs generally offering a more predictable response and not requiring routine monitoring of blood clotting times [1].
What is the Significance of Generic Entry for Drug Pricing?
The introduction of generic drugs typically leads to a significant decrease in drug prices. This can make medications more affordable and accessible to a wider patient population.
*
**Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] https://www.drugpatentwatch.com/drug/rivaroxaban/generics